With the recent discovery of numerous FLT3 inhibitor-responsive serine/threonine and tyrosine phosphorylation sites uncovered in primary AML patient bone marrow samples [22], identification of protein kinase inhibitors that are able to enhance the potency of FLT3 inhibitors makes intuitive sense. Here, WEE1 is linked to acute myeloid leukemia.